NRAS G12S

CI-VAR-00001617Explore in graph →NP_002515.1:p.Gly12SerNM_002524.4:c.34G>AClinVar 177778 CIViC 898 rs121913250

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm3
NRAS G12S	Dactolisib	Predictive	C	Supports Sensitivity Response	—	rejected	EID2216 NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer. PMID 17384584 · Schubbert et al., 2007 · Open in CIViC	civic
NRAS G12S	Dactolisib	Predictive	D	Supports Sensitivity Response	—	submitted	EID2215 In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabiliza… (full text at CIViC) PMID 22392911 · Migliardi et al., 2012 · Open in CIViC	civic
NRAS G12S

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
177778	Pathogenic	reviewed by expert panel	3	Juvenile myelomonocytic leukemia; Noonan syndrome; RASopathy; Noonan syndrome and Noonan-related syndrome; Noonan syndrome 6; Neoplasm; Colorectal cancer; NRAS-related disorder	germline/somatic	13	Dec 03, 2024	clinvar